NCT03373396 (HEPATOCHLORD) is a NA clinical trial of Blood samples in Fibrosis, Liver, sponsored by Centre Hospitalier Universitaire de la Guadeloupe.

Who is sponsoring NCT03373396?

NCT03373396 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe.

What drugs are being tested in NCT03373396?

Interventions in NCT03373396: Blood samples.

What condition does NCT03373396 study?

NCT03373396 studies Fibrosis, Liver.

Is NCT03373396 still recruiting?

NCT03373396 is currently completed. Last updated 14 December 2017.

Last reviewed 2017-12-14 · How we verify

NCT03373396: HEPATOCHLORD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Chlordecone on Active Chronic Hepatitis

Completed NA Last updated 14 December 2017

What this trial tests

NA trial testing Blood samples in Fibrosis, Liver in 283 participants. Completed in 21 December 2015.

Timeline

8 November 2011

Primary endpoint
21 December 2015

21 December 2015

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de la Guadeloupe
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	283
Start date	8 November 2011
Primary completion	21 December 2015
Estimated completion	21 December 2015
Sites	1 location across Guadeloupe

Drugs / interventions tested

Blood samples — full drug profile →

Conditions studied

Fibrosis, Liver — all drugs for Fibrosis, Liver →

Sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Who can join

18 and older, any sex, with Fibrosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chlordecone is known to induce liver damage in rat and mice but no data exists in human being. However chlordecone was used until 1993 in French West Indies for banana fields, it is important to test what damage can be induced now, for patients exposed. We should consider chlordecone as a potential cofactor of liver fibrosis. So we have chosen to compare two populations of chronic hepatitis B, C or alcoholic, with cirrhosis or without fibrosis due to active hepatitis, who had been exposed to chlordecone.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inverse association between plasma chlordecone concentrations and progression of alcoholic liver fibrosis: the role of liver metabolism.
Gelu-Simeon M, Lafrance MJ, Michineau L, Saillard E, et al · · 2024 · cited 1× · PMID 38504260 · DOI 10.1186/s12940-024-01054-6

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

NCT07460700 — Mesenteric Ischemia Markers Study · NA · recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06694363 — New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome · recruiting
NCT06826066 — Involvement of the Immune System in Intrinsic Radiosensitivity · NA · recruiting
NCT06864481 — Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis · recruiting

Other recruiting trials for Fibrosis, Liver

Currently open trials in the same condition.

NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
NCT06814600 — Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients · recruiting
NCT06366425 — Screening for Chronic Liver Diseases in General Population · NA · recruiting
NCT06564740 — Stem Cell Applications in Biliary Atresia Patients · NA · recruiting
NCT05692024 — COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER · Phase 1, PHASE2 · recruiting

Other Centre Hospitalier Universitaire de la Guadeloupe trials

Trials by the same sponsor.

NCT07266376 — Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS · NA · not yet recruiting
NCT07292454 — Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe · not yet recruiting
NCT07265986 — Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart · NA · recruiting
NCT07330830 — Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (A · recruiting
NCT07233447 — Prevalence of H. Pylori in Stomach Cancers in the West Indies · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03373396 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de la Guadeloupe
Last refreshed: 14 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03373396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing